Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB)in patients with nonhealing, lower extremity diabetic ulcers: A combined analysis of four randomized studies

Wound Repair and Regeneration

Volumn 7, Issue 5, 1999, Pages 335-346

  Smiell, J M ^a   Wieman, T J ^a   Steed, D L ^a   Perry, B H ^a   Sampson, A R ^a   Schwab, B H ^a  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN; PLATELET DERIVED GROWTH FACTOR BB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEBRIDEMENT; DIABETIC FOOT; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN ULCER; TOPICAL DRUG ADMINISTRATION; ULCER; ULCER HEALING; WOUND CARE;

EID: 0032720053     PISSN: 10671927     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-475X.1999.00335.x     Document Type: Article

References (18)